Synthesis and in vitro activities on anti-platelet aggregation of 4-methoxy-1,3-phthalamidesamides and benzenedisulfonamides

  • Guangling ChenEmail author
  • Chaoqing Wang
  • Zhihao Zhang
  • Xiujie LiuEmail author
Original Research


Cardiovascular diseases are the most frequent cause of morbidity and mortality worldwide. In order to discover novel compounds with anti-platelet aggregation activities, a series of novel 4-methoxy-1,3-phthalamidesamides (1a1i) and a series of novel 4-methoxy-1,3-benzenedisulfon-amides (2a2i) were synthesized and their anti-platelet aggregation activities were evaluated by the turbidimetric method in response to the following agonists: adenosine diphosphate (ADP), arachidonic acid (AA), and Collagen. Those compounds that have better in vitro activities were subjected to cell toxicity tests via cell counting kit-8 (CCK-8) assay. The inhibition rates of anti-platelet in vitro of five compounds 1g (39.45%), 2d (38.87%), 2g (38.55%), 2h (44.56%), and 2i (43.93%) were higher than that of two reference drugs picotamide (36.12%) and aspirin (38.45%) when ADP was selected as an inducer. The inhibition rates of seven compounds 1c (43.63%), 1d (40.02%), 1g (47.42%), 1i (40.45%), 2c (40.11%), 2d (40.45%), and 2i (49.05%) were higher than that of picotamide (34.89%) and aspirin (39.43%) when AA was selected as inducer. And the inhibition rates of five compounds 1d (47.22%), 1i (45.01%), 2d (38.74%), 2e (42.21%), and 2f (39.94%) were higher than picotamide (38.45%) and aspirin (37.08%) when collagen was selected as inducer. Moreover, the effect of cell toxicity exhibited that none of the compounds had obvious cell toxicity against L-929 cells. Therefore, 4-methoxy-1,3-phthalamidesamides (1a1i) and 4-methoxy-1,3-benzenedisulfon-amides (2a2i) have the potential to become a novel kind of anti-platelet drugs and deserve further study.


4-Methoxy-1,3-phthal-amides 4-Methoxy-1,3-benzenedisulfon-amides Synthesis Picotamide Anti-platelet activity 



The authors are grateful to the National Science Foundation of China (11341014) and the Committee of Science and Technology of Tianjin of China (15JCZDJC33100) for the financial supports and Shenyang Pharmaceutical University of China for running platelet aggregation assays.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS (2007) A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 153(1):0-2147483647CrossRefGoogle Scholar
  2. Benimana O, Zhao L, Kong Y, Li Z, Xie Z (2017) The progress in the research of anti-platelet agents (1995–2017). Future Med Chem 9(10):1087–1110CrossRefGoogle Scholar
  3. Bir SC, Maiti TK, Bollam P, Nanda A (2015) Felix platter and a historical perspective of the meningioma. Clin Neurol Neurosurg 134(21):75–78CrossRefGoogle Scholar
  4. Born GV (1962) Aggregation of blood platelets by adenosine diphosphate and its reveasal. Nature 194:927–929CrossRefGoogle Scholar
  5. Chelucci RC, Dutra LA, Pires ME, Melo TR, Bosquesi PL, Chung MC (2014) Anti-platelet and antithrombotic activities of non-steroidal anti-inflammatory drugs containing an n-acyl hydrazone subunit. Molecules 19(2):2089CrossRefGoogle Scholar
  6. Liu XJ, Wang CQ, Wang X, Zhang QX, Liu K (2016) Synthesis and antiplatelet aggregation activities in vitro of N,N-di(3-substitutedphenyl)-4-methoxyl benzene-1,3-disulfonamides. J Pharm Pharm Sci 4:72–76Google Scholar
  7. Lourenço AL, Rrs S, Silva LA, Saito MS, Jfr M, Cabral LM (2017) Synthesis and mechanistic evaluation of novel n’-benzylidene-carbohydrazide-1h-pyrazolo[3,4-b]pyridine derivatives as non-anionic anti-platelet agents. Eur J Med Chem 135:213–229CrossRefGoogle Scholar
  8. Liu XJ, Shi XX, Zhong YL, Liu N, Liu K (2012) Design, synthesis and in vitro activities on anti-platelet aggregation of 4-methoxybenzene-1,3-isophthalamides. Bioorg Med Chem Lett 22(21):6591–6595CrossRefGoogle Scholar
  9. Liu XJ, Wang CQ, Meng J, Shi XX, Yan YN, Liu XG (2017) Design, synthesis and biological evaluation of 4-methoxy diaryl isophthalates as anti-platelet agents. Med Chem Res 1:1–9Google Scholar
  10. Mirfazli SS, Kobarfard F, Firoozpour L, Asadipour A, Esfahanizadeh M, Tabib K (2014) N-substituted indole carbohydrazide derivatives: synthesis and evaluation of their anti-platelet aggregation activity. Daru 22(1):65CrossRefGoogle Scholar
  11. Machlus KR, Thon JN, Italiano JE (2014) Interpreting the developmental dance of the megakaryocyte: a review of the cellular and molecular processes mediating platelet formation. Br J Haematol 165(2):227–236CrossRefGoogle Scholar
  12. Patrono C, Coller B, Dalen JE, Fitzgerald GA, Fuster V, Gent M (2001) Platelet-active drugs. The relationship among dose, effectiveness and side effects. Chest 119(1):39S–63SCrossRefGoogle Scholar
  13. Storey RF (2006) Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des 12(10):1255–1259CrossRefGoogle Scholar
  14. Wang Y, Wang X, Chen X, Liu XJ (2018) Synthesis and in vitro anti-platelet aggregation activities of 2-methoxy-5-arylamido-N-(pyridin-3-yl-methyl)benzamides. Arch Pharm (Weinheim) 352(1):e1800257Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Tianjin University of TechnologyTianjinPR China
  2. 2.Tianjin Key Laboratory of Organic Solar Cells and Photochemical ConversionSchool of Chemistry and Chemical EngineeringTianjinPR China

Personalised recommendations